Brand Name

Vabomere

Generic Name
Meropenem-Vaborbactam
View Brand Information
FDA approval date: October 02, 2017
Classification: Penem Antibacterial
Form: Injection

What is Vabomere (Meropenem-Vaborbactam)?

VABOMERE is a combination of meropenem, a penem antibacterial, and vaborbactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years and older with complicated urinary tract infections including pyelonephritis caused by designated susceptible bacteria.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

An Open-label, Multicentre, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VaboremⓇ (Meropenem-Vaborbactam) in Paediatric Population With Suspected or Confirmed Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections
An Open-label, Multicentre, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VaboremⓇ (Meropenem-Vaborbactam) in Paediatric Population With Suspected or Confirmed Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections
Enrollment Status: Recruiting
Publish Date: February 04, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: The goal of this clinical trial is to assess the pharmacokinetic (PK) and safety and tolerability of Vaborem (fixed combination of meropenem and vaborbactam) in the paediatric population aged from birth to \< 18 years with suspected or confirmed Gram negative infections in need of hospitalisation and intravenous (IV) antibiotic administration. All participants will receive Vaborem IV every 8 hours...

TREAT-GNB [CR-GNB]
TREAT-GNB [CR-GNB]
Enrollment Status: Recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 4

Summary: TREAT-GNB is an innovative trial to expedite the evaluation of various antibiotic choices and treatment strategies for severe multidrug-resistant Gram-negative bacterial infections, specifically bloodstream and lower respiratory tract infections. This approach combines platform trial elements with adaptive clinical designs to streamline the evaluation of various treatment options and optimise reso...

View All Clinical Trials

Related Latest Advances

In vitro susceptibility of Stenotrophomonas maltophilia and other carbapenem non-susceptible Gram-negative rods in the Pacific Northwest to cefiderocol and aztreonam-avibactam.
In vitro susceptibility of Stenotrophomonas maltophilia and other carbapenem non-susceptible Gram-negative rods in the Pacific Northwest to cefiderocol and aztreonam-avibactam.
Journal: JAC-antimicrobial resistance
Published: June 10, 2026
Global Survey on the Management of Multidrug-resistant Gram-negative Bacilli: Divergence of Practice Between High-Income Countries and the Rest of the World.
Global Survey on the Management of Multidrug-resistant Gram-negative Bacilli: Divergence of Practice Between High-Income Countries and the Rest of the World.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: June 02, 2026
Treatment of Post-Neurosurgical Ventriculitis and Scalp Infection Caused by Klebsiella pneumoniae Carbapenemase and New Delhi Metallo-β-Lactamase Co-Producing Carbapenem-Resistant Klebsiella pneumoniae: A Case Report.
Treatment of Post-Neurosurgical Ventriculitis and Scalp Infection Caused by Klebsiella pneumoniae Carbapenemase and New Delhi Metallo-β-Lactamase Co-Producing Carbapenem-Resistant Klebsiella pneumoniae: A Case Report.
Journal: Cureus
Published: May 15, 2026
View All Latest Advances